-
May 15, 2013
Core operating performance at Agilent needs to improve
-
February 11, 2013
FEI has excellent growth potential, but valuation is a bit steep.
-
January 22, 2013
Waters Corporation (WAT) released its fourth-quarter and fiscal 2012 earnings before the market opened today. The ...
-
October 23, 2012
Waters Corporation (WAT) released its third-quarter 2012 earnings before the market opened today, reporting earnings ...
-
October 16, 2012
New York, May 17th (TradersHuddle.com) - These are the research analyst new ratings before the market open.
Crocs ...
-
July 10, 2012
After a shockingly mild winter across most of the U.S., many were hoping for a similarly mild summer too. However, ...
-
June 29, 2012
We maintain a Neutral recommendation on Waters Corporation (WAT). The company reported disappointing first-quarter ...
-
May 16, 2012
Agilent looks poised for a EMG rebound.
-
April 10, 2012
Forget the nano hype, FEI is a real company in the analytical technology space.
-
December 30, 2011
Neogen has to do more to validate this price.
-
November 30, 2011
It may be time to consider Life Tech as a good blue-chip play in the health-care sector.
-
October 10, 2011
Illumina and competitors get hit by weak academic spending. Optimism remains, however, with the pull of new and ...
-
September 20, 2011
Finding new healthcare solutions will be a paramount concern going forward. For investors, the best way to profit ...
-
September 13, 2011
Caliper's rebound comes to an end with a premium take-out by PerkinElmer.
-
August 17, 2011
Agilent continues to deliver the results, quarter after quarter.
-
August 04, 2011
Illumina's sky-high valuation takes a beating on lower guidance.
-
May 17, 2011
Agilent has more than made up for lost time and is emerging as a popular growth company with multiple streams of ...
-
April 29, 2011
Illumina is a torrid grower, and growth investors seem to be willing to pay any price.
-
December 15, 2010
Thermo Fisher makes a very reasonable purchase but pays a price to do so.
-
October 29, 2010
The life sciences field is showing encouraging growth and mostly reasonable valuations.
